SCHEMBL459369

SCHEMBL459369

Fc1ccccc1CCBr

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.62
AOC3 Q16853 1/20 0.50
IDO1 P14902 2/20 0.46
MPO P05164 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 1/20 0.42
MAOB P27338 2/20 0.42
DAO P14920 2/20 0.42
HPGD P15428 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.40
GLA P06280 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447918 1.00 TAAR1 (0.62) TAAR1AOC3IDO1MPOTDP1
SCHEMBL27532195 0.88 TAAR1 (0.50) TAAR1AOC3IDO1MPOLMNA
SCHEMBL79807 0.86 TAAR1 (0.58) TAAR1AOC3IDO1MPOLMNA
SCHEMBL8077488 0.84 TAAR1 (0.56) TAAR1AOC3IDO1MPOLMNA
SCHEMBL8526001 0.84 TAAR1 (0.75) TAAR1AOC3IDO1MPOLMNA
SCHEMBL11805787 0.82 TAAR1 (0.43) TAAR1AOC3IDO1MPOTDP1
SCHEMBL8073119 0.82 TAAR1 (0.54) TAAR1AOC3IDO1MPOLMNA
SCHEMBL8075974 0.82 TAAR1 (0.54) TAAR1AOC3IDO1MPOLMNA
SCHEMBL7564094 0.82 TAAR1 (0.54) TAAR1AOC3IDO1MPOLMNA
SCHEMBL8072531 0.82 TAAR1 (0.54) TAAR1AOC3IDO1MPOLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117177975-B Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2026-05-19 CN disclosed
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 EP disclosed
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 US disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORPORATION (JP) 2025-10-23 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
WO-2025104092-A1 MODULATORS OF SEPTIN 6 FOR USE IN THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2025-05-22 WO disclosed
WO-2025104081-A1 TRIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2025-05-22 WO disclosed
CN-119528906-A Azaspiro compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-02-28 CN disclosed
US-5064565-A Liquid crystals CHISSO CORPORATION (JP) 1991-11-12 US disclosed
CN-1014515-B Process for preparing nonaromatic fluoroallylamine as MAO inhibitor MERRELL DOW PHARMA (US) 1991-10-30 CN disclosed
EP-0224794-B1 CYCLIC AMINE DERIVATIVES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION Dr. Karl Thomae GmbH (DE) 1990-09-12 EP disclosed
EP-0383950-A1 PYRIDINE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT IDEMITSU KOSAN COMPANY LIMITED (JP) 1990-08-29 EP disclosed
CN-86108051-A NONAROMATIC FLUOROALLYLAMINE MAO INHIBITORS 1987-08-19 CN disclosed
EP-0224794-A2 Cyclic amine derivatives, medicines containing these compounds and process for their preparation Dr. Karl Thomae GmbH (DE) 1987-06-10 EP disclosed
US-4633026-A DEHYDROHALOGENATION OF RING-HALOGENATED ALPHA- OR BETA-BROMOETHYL BENZENES WITH STRONG BASE, POLYOXYETHYLENE GLYCOL CATALYST, AMINE POLYMERIZATION INHIBITOR ETHYL CORPORATION (US) 1986-12-30 US disclosed
US-4292453-A REACTION OF A HALO DERIVATIVE OF BETA-BROMOETHYLBENZENE WITH AQUEOUS ALKALI AND A QUATERNARY PHASE TRANSFER CATALYST MAKHTESHIM CHEMICAL WORKS LTD. (IL) 1981-09-29 US disclosed
US-4150135-A ANALGESICS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1979-04-17 US disclosed
US-4017631-A MICROBIOCIDES JANSSEN PHARMACEUTICA N.V. (BE) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS TAAR1 3383/4885AOC3 2144/4885IDO1 3206/4885
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same NQO1, CBR1, NFE2L2 TAAR1 2115/4885AOC3 292/4885IDO1 403/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD TAAR1 3353/4885AOC3 2128/4885IDO1 3200/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 TAAR1 3573/4885AOC3 492/4885IDO1 2074/4885
US-20250326744-A1 PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION ABCB11, ABCC1, SLC11A2 TAAR1 2444/4885AOC3 4327/4885IDO1 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.